Components:
Method of action:
Medically reviewed by Kovalenko Svetlana Olegovna, PharmD. Last updated on 29.03.2022
Attention! Information on this page is intended only for medical professionals! Information is collected in open sources and may contain significant errors! Be careful and double-check all the information on this page!
Top 20 medicines with the same components:
Acamprosate is indicated as therapy to maintain abstinence in alcohol-dependent patients. It should be combined with counselling.
Posology
Adults within the age range 18-65 years:
- 2 tablets three times daily with meals (2 tablets morning, noon and night) in subjects weighing 60kg or more.
- In subjects weighing less than 60kg, 4 tablets divided into three daily doses with meals (2 tablets in the morning, 1 at noon and 1 at night).
Older people
Acamprosate should not be used in older people
Paediatric population
Acamprosate should not be used in children
The recommended treatment period is one year. Treatment with acamprosate should be initiated as soon as possible after the withdrawal period and should be maintained if the patient relapses.
Acamprosate does not prevent the harmful effects of continuous alcohol abuse. Continued alcohol abuse negates the therapeutic benefit, therefore acamprosate treatment should only be initiated after weaning therapy, once the patient is abstinent from alcohol.
−
− Lactating women
− In cases of renal insufficiency (serum creatinine >120 micromol/L)
The safety and efficacy of Acamprosate Biogaran has not been established in patients younger than 18 years or older than 65 years. Acamprosate Biogaran is therefore not recommended for use in these populations.
The safety and efficacy of Acamprosate Biogaran has not been established in patients with severe liver insufficiency (Childs-Pugh Classification C).
Because the interrelationship between alcohol dependence, depression and suicidality is well-recognised and complex, it is recommended that alcohol-dependent patients, including those treated with acamprosate, be monitored for such symptoms.
Abuse and dependence
Non-clinical studies suggest that acamprosate has little or no abuse potential. No evidence of dependence on acamprosate was found in any clinical study thus demonstrating that acamprosate has no significant dependence potential.
Acamprosate Biogaran has no influence on the ability to drive and use machines.
According to information collected during clinical trials and spontaneous reports since marketing authorization, the following adverse reactions may occur under treatment with Acamprosate Biogaran.
The following definitions apply to the frequency terminology used hereafter:
very common (> 1/10), common (> 1/100, < 1/10), uncommon (> 1/1,000, < 1/100), rare (> 1/10,000, < 1/1,000), very rare (< 1/10,000, including isolated cases), frequency not known (cannot be estimated from the available data)
Gastrointestinal disorders:
Very common: Diarrhoea
Common: Abdominal pain, nausea, vomiting, flatulence
Skin and subcutaneous tissue disorders:
Common: Pruritus, maculo-papular rash
Not known: Vesiculo-bullous eruptions
Immune system disorders:
Very rare: Hypersensitivity reactions including urticaria, angio-oedema or anaphylactic reactions.
Reproductive system and breast disorders:
Common: Frigidity or impotence.
Psychiatric disorders:
Common: Decreased libido
Uncommon: Increased libido
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard.
Acute overdose is usually mild. In the reported cases, the only symptom, which can be reasonably related to overdose is diarrhoea. No case of hypercalcaemia has ever been reported. Treatment of overdose is directed to symptoms.
Acamprosate (calcium acetylhomotaurinate) has a chemical structure similar to that of amino acid neuromediators, such as taurine or gamma-amino-butyric acid (GABA), including an acetylation to permit passage across the blood brain barrier. Acamprosate may act by stimulating GABAergic inhibitory neurotransmission and antagonising excitatory amino-acids, particularly glutamate. Animal experimental studies have demonstrated that acamprosate affects alcohol dependence in rats, decreasing the voluntary intake of alcohol without affecting food and total fluid intake.
Acamprosate absorption across the gastrointestinal tract is moderate, slow and sustained and varies substantially from person to person. Food reduces the oral absorption of acamprosate. Steady state levels of acamprosate are achieved by the seventh day of dosing. Acamprosate is not protein bound.
Oral absorption shows considerable variability and is usually less than 10% of the ingested drug in the first 24 hours. The drug is excreted in the urine and is not metabolised significantly. There is a linear relationship between creatinine clearance values and total apparent plasma clearance, renal clearance and plasma half-life of acamprosate.
The kinetics of acamprosate are not modified in group A or B of the Child-Pugh classification of impaired liver function, a population which is likely to be part of the target population for acamprosate. This is in accordance with the absence of hepatic metabolism of the drug.
In the preclinical studies, signs of toxicity are related to the excessive intake of calcium and not to acetylhomotaurine. Disorders of phosphorus/calcium metabolism have been observed including diarrhoea, soft tissue calcification, renal and cardiac lesions. Acamprosate had no mutagenic or carcinogenic effect, nor any teratogenic or adverse effects on the male or female reproductive systems of animals. Detailed in vitro and in vivo research on acamprosate to detect genetic and chromosomal mutations has not produced any evidence of potential genetic toxicity.
Not applicable
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
Epigenetic Regulation of Circadian Clocks and Its Involvement in Drug Addiction
The Role of Taurine in Mitochondria Health: More Than Just an Antioxidant
Exploring regulation and function of dopamine D3 receptors in alcohol use disorder. A PET [11C]-(+)-PHNO study
A new strategy to uncover fragile X proteomic biomarkers using the nascent proteome of peripheral blood mononuclear cells (PBMCs)
Selective Inhibition of Phosphodiesterase 7 Enzymes Reduces Motivation for Nicotine Use through Modulation of Mesolimbic Dopaminergic Transmission
Lactulose Improves Neurological Outcomes by Repressing Harmful Bacteria and Regulating Inflammatory Reactions in Mice After Stroke
The Impact of Direct-acting Antiviral Therapy on End Stage Liver Disease Among Individuals with Chronic Hepatitis C and Substance Use Disorders
THE USE OF ALL-ORAL DIRECT ACTING ANTIVIRALS IN HEPATITIS C VIRUS INFECTED PATIENTS WITH SUBSTANCE USE DISORDERS
Facilitating rapid access to addiction treatment: a randomized controlled trial
Veteran adherence to oral versus injectable AUD medication treatment
Use of Nalmefene in Routine Practice: Results from a French Prospective Cohort Study and a National Database Analysis
Wuzhi capsule increased systemic exposure to methotrexate by inhibiting the expression of OAT1/3 and P-gp
FMRI-based prediction of naltrexone response in alcohol use disorder: a replication study
Antisocial Personality Disorder Among Patients in Treatment for Alcohol Use Disorder (AUD): Characteristics and Predictors of Early Relapse or Drop-Out
Nalmefene attenuates neural alcohol cue-reactivity in the ventral striatum and subjective alcohol craving in patients with alcohol use disorder
Effect of alcohol on the central nervous system to develop neurological disorder: pathophysiological and lifestyle modulation can be potential therapeutic options for alcohol-induced neurotoxication
The role of antiresorptive drugs and medication-related osteonecrosis of the jaw in nononcologic immunosuppressed patients: A systematic review
Incidence and management patterns of alcohol-related liver disease in Korea: a nationwide standard cohort study
Group versus individual treatment for substance use disorders: a study protocol for the COMDAT trial
A Gender Perspective of Addictive Disorders
However, we will provide data for each active ingredient